Antibody Effector Mechanisms in Immune Therapy

A01  Ex vivo evaluation of an anti-Müllerian hormone type II receptor humanized antibody with optimized Fc effector function in ovarian cancer. Houcine Bougherara, Fariba Némati, Christophe De Romeuf, Jean-Marc Barret, Gérald Massonnet, Marie-Aude Le Frère-Belda, Jean-François Prost, Didier Decaudin, Emmanuel Donnadieu.

A02  The art of omission: Low fucose antibodies enhance tumor cell clearance in vivo. Rens Braster, Remco Visser, Gestur Vidarsson, Marjolein van Egmond.


A04  Systemic agonistic anti-CD40 treatment of tumor bearing mice modulates hepatic myeloid suppressive cells and causes immune-mediated liver damage. Jose Medina-Echeverz, Chi Ma, Tobias Eggert, Tim F Greten.

A05  Combining the long-acting engineered cytokine NKTR-214 with checkpoint inhibitors is synergistic and shows long lasting anti-tumor immunity in murine tumor models. Seema Kantak, Rhoneil Pena, Murali Addepalli, Steve Lee, Kirksey Yolanda, Rupesh Kanhere, Priyam Jha, Ute Hoch, Deborah Charych, Stephen K Doberstein.

A06  Identification and characterization of a potent anti-human TIM-3 antagonist. Jean da Sliva Correia, Marilyn Kehry, Margaret Marino, Haley Laken, David J King.

A07  Combining CTLA4 and PD-L1 blockade leads to complete eradication of metastatic osteosarcoma. Danielle M Lussier, John L Johnson, Pooja Hingorani, Joseph N Blattman.

A08  Distribution, cutoff, and functional significance of a potential biomarker for Imprime PGG, an experimental cancer immunotherapeutic, in a healthy subject population. Diane McMurray, Ben Harrison, Katie Ertelt, Richard Walsh, Lindsay Wurst, Steven Leonardo, Nadine Ottoson, Adria Bykowski Jonas, Xiaohong Qiu, Nandita Bose, Peter Maimonis.


A10  Soluble CD25 and C-reactive protein predict overall survival in melanoma patients receiving anti-CD40 monoclonal antibody CP-870,893 (αCD40) and anti-CTLA4 monoclonal antibody tremelimumab. Rosemarie Mick, David Bajor, Lee Richman, Robert Vonderheide.

A11  Activity of a bispecific antibody targeting EGFR and cMet with enhanced Fc effector function in EGFR mutant setting with cMet pathway activation. Keri L Soring, Katharine D Grugan, Randall J Breszki, Jose Pardinas, Leopoldo Luistro, Barbara Bushey, Joost Neijssen, Paul Parren, Janine Schuurman, Mark Anderson, Ricardo Attar, Matthew V Lorenzi, Mark Chiu, Sheri Moores.

A13  Humanized mouse models for in vivo evaluation of anti-human cancer immunotherapeutics.  Juan Zhang, Meng Qiao, Qian Shi.

A14  Overcoming therapeutic MAb resistance in aggressive HER2 positive breast carcinomas by adoptive immunotherapy using optimized effector cells.  Sandrine Valsesia-Wittmann, Beatrice Clemenceau, Anne-Catherine Jallas, Jean-Yves Blay, Aurelien Marabelle, Christophe Caux, Henri Vie.


A16  High αV integrin level in melanoma cells is associated with development of brain metastasis in athymic rats.  Jeffrey Wu, Michael A. Pagel, Leslie L Muldoon, Edward A. Neuwelt.

Interaction of Radiobiology

A17  The role of radiation-induced TGF-β in the generation of MDSCs.  Alba Gonzalez-Junca, Ilenia Pelicciotta, Kyla Elizabeth Discroll, Mary Helen Barcellos-Hoff.


A20  A systematic evaluation of abscopal responses following radiation therapy in patients with metastatic melanoma treated with ipilimumab.  Ravi A. Chandra, Tyler J. Wilhite, Tracy A. Balboni, Alexander Spektor, Andrea K. Ng, Frank Stephen Hodi, Jonathan D. Schoenfeld.

A21  Adenosine is a rheostat for radiation therapy-induced immune activation.  Erik Wennerberg, Noriko Kawashima, Sandra Demaria.


A30  Anti-tumor effect of natural killer cells in human PBMCs against ovarian cancer.  Veethika Pandey, Jeremiah L Oyer, Robert Y Igarashi, Susan B Ingersoll, Alicja J Copik, Deborah A Altomare.


A33  Preparation of local anti-wart and anti-inflammatory rub of polyglycidol based saturated lipid (DDP-PG) with HPMC containing curcumin.  Sharif Mohammad Shaheen, Pavel Bakardzhiev, Denitsa Momkova, Neli S. Koseva, Stanislav Rangelov.


A36  Novel therapeutic approaches for human malignant mesothelioma.  Haining Yang, Sandro Jube, Michele Carbone.
Overcoming Obstacles to Generating Adaptive Immunity

A37 Immunization of cutaneous melanoma patients with the allogeneic cell vaccine CSF-470 enhances immune infiltration of metastatic lesions and would favor subsequent response to Vemurafenib. Mariana Aris, María Betina Pampena, Estrella M Levy, Alicia I Bravo, Florencia P Madorsky-Rowdo, Ana Mordoh, Julio Kaplan, Antonela Baron, Mariela Urrutia, Paula A Blanco, María Marcela Barrio, José Mordoh.


A39 Targeting tumor infiltrating myeloid cells with a potent CCR1 small molecule antagonist. Ashley G Bischof, Joanne BL Tan, Sreenivas Punna, Penglie Zhang, Israel Charo, Anne-Marie Duliege, Thomas Schall.

A41 Galectin-9 has tumor promoting properties that may be targetable in metastatic melanoma. Elizabeth Ann L Enninga, Wendy K Nevala, Svetomir N Markovic.

A42 MK-1775, a WEE1 inhibitor alleviates resistance to immune attack of tumor cells undergoing an epithelial-mesenchymal transition. Duane H Hamilton, Romaine I Fernando, Kwong-Yok Tsang, Claudia Palena.


A44 Checkpoint inhibition of adaptive immunity by IL-9 can be disrupted to achieve rapid T cell sensitization and rejection of progressive tumor challenges. Dominique B Hoelzinger, Ana Lucia Dominguez, Peter A Cohen, Sandra J Gendler.

A45 Cyclin-dependent Kinase 5 regulates gamma-interferon induced PD-L1 up-regulation in solid tumors. Agne Petrosiute, Joseph Nthale, Gabby Valdivieso, R. Dixon Dorand, Tej Kumar Pareek, Deborah Sim Barkauskas, Jay T. Myers, John J. Letterio, Duncan Stearns, Alex Yee-Chen Huang.

A46 Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 and B16 mouse melanoma. Bruce Freimark, Jian Gong, Dan Ye, Van Nguyen, Shen Yin, Rich Archer, Chris Hughes, Jeff Hutchins, Jeff Hutchins, Alan Schroit, Rolf Brekken, Xianming Huang.

A48 Vaccine maneuvers which reverse tolerance to MUC1 requires antigenic diversity to mediate protection and delay immunoedited escape variants. Vani Lakshminarayanan, Nitin Supekar, Dustin B McCurry, Jei Wei, Cathy S Madsen, Judy M Bradley, Latha B Pathangey, Margreet A Wolfret, Geert Jan Boons, Peter A Cohen, Sandra J Gendler.


A53 Expression of immune checkpoint modulators on CD4+ and CD8+ T cells coincides with activation during the priming phase of an allogeneic response. Nina Chi Sabins, Benjamin Harman, Linda Barone, Sandra Santulli-Marotto.

A54 Laser-assisted intradermal delivery of Xcl1-specific fusion vaccines induces potent anti-tumor response. Dorothea Terhorst, Dorothea Terhorst, Even Fossum, Bjarne Bogen, Sandrine Henri, Bernard Malissen.


A58 JAK1 deficiency as a novel mechanism of tumor immune escape in uterine cancer. Yuan Ren, Yonghong Zhang, Richard Z Liu, David A Fenstermacher, Kenneth L Wright, Jamie K Teer, Jie Wu.
Tumor Immunology and Immunotherapy: A New Chapter
Poster Session A, Tuesday, December 2, 2014, 1:15-3:30 p.m.

Tumor Microenvironment


A60  Synergistic effect of targeted chemotherapy delivery using theranostic nanoparticles and PD-L1 blockade in an orthotopic mouse pancreatic cancer model.  Erica N Bozeman, Ning Gao, Weiping Qian, Andrew Wang, Lily Yang.

A61  A clinical stage TLR5 agonist EntolimodTM activates T cell immunity against liver metastases via CXCR3-coordinated NK cell recruitment to the liver.  Craig Brackett, Bojidar Kojouharov, Jean Veith, Sandra Gollnick, Lyudmila Burdelya, Scott Abrams, Andrei Gudkov.

A62  Immune and T cell receptor heterogeneity in distinct tumors within individual melanoma patients.  Alexandre Reuben, Rodabe N Amaria, Cara Haymaker, Marie Andree Forget, Chantale Bernatchez, Pei-ling Chen, Michael Tetzlaff, Michael A Davies, Karen C Dwyer, Jennifer A Wargo, Zachary A Cooper.

A63  The role of DARC in the immunological tumor microenvironment of breast cancer.  Melissa B Davis, Michele Monteil, Rupali Hire, Elizabeth W Howerth.

A64  Chronic allergic contact dermatitis, A potent tumor promoter of Marjolin’s ulcer.  Shadmehr Demehri, Trevor J Cunningham, Eva A Hurst, Andras Schaffer, David M Sheinbein, Wayne M Yokoyama.


A66  Tumor-associated neutrophils in early stage human lung cancer are not immunosuppressive, but exhibit an inflammatory phenotype and provide accessory signals for T cell activation.  Evgeniy Eruslanov, Pratik Bhojnagarwala, Jon Quatromoni, Tom Stephen, Anjana Ranganathan, Charuhas Deshpande, Tatiana Akimova, Anil Vachani, Leslie Litzky, Wayne Hancock, Jose Conejo-Garcia, Michael Feldman , Sunil Singhal, Steven Albeda.


A68  Local tumor treatments to simulate systemic antitumor immune responses.  Patrick Lizotte, Mee Rie Sheen, Amy M Wen, Nicole F Steinmetz, Steven Fiering.
A69  The immunological environment in triple negative breast cancer; impact on clinical outcomes towards a prognostic clinical test.  Mathieu Gigoux, Tina Gruosso, Nicholas Bertos, Sadiq Saleh, Atilla Omeroglu, Hong Zhao, Margarita Souleimanova, Sarkis Meterissian, Michael Hallett, Morag Park.


A73  Clinical significance of tumor-infiltrating immune cells focusing on BTLa and Cbl-b in patients with gallbladder cancer.  Seiji Oguro, Yoshinori Ino, Kazuaki Shimada, Yutaka Hatanaka, Yoshihiro Matsuno, Tomoo Kosuge, Nobuyoshi Hiraoka.

A74  Spatial organization of myeloid cells in tumor microenvironment.  Minhyeok KIM, Seon Woo LEE, Suk-Jo KANG, Changwon KANG.

A75  The CD8:M2 ratio by digital multiplex gene expression permits accurate quantification of net intra-tumoral immunity within the tumor microenvironment in DLBCL.  Colm Keane, Frank Vari, Mark Hertzberg, John Seymour, Kim Anh Le Cao, Devinder Gill, Rodney Hicks, Michael Green, Kristen Radford, Lyn Griffiths, Dipti Talaulikar, Maher K Gandhi.

A76  Immune mechanisms and racial disparities in colon cancer.  Mohammad W Khan, Mengxi Tian, John M Carethers, Kathleen L McGuire.

A77  Differential recruitment of myeloid derived immune cells and fibroblasts to the thyroid tumor microenvironment in mouse models of papillary and follicular thyroid cancer.  Lee Ann King, Sergey Novitsky, Julio Ricarte-Filho, Philip Owens, Aime T. Franco.


A79  The prognostic importance of Th1 cell infiltration in colorectal cancer and mechanisms of immune regulation.  Agnes Ling, Sofia Edin, Maria L Wikberg, Åke Öberg, Richard Palmqvist.


A83 The role of Ikaros in effector and regulatory T cell homeostasis in a murine pancreatic cancer model. *Nadine Nelson*, Shengyan Xiang, Xiaohong Zhang, Karoly Szekeres, Ghansah Tomar.


A89 PPARγ induced TGFβ expression in myeloid cells contributes to lung cancer metastasis. *Trisha R Sippel*, Howard Li, Dwight Hanson, Lisa Greene, Bonnie Bullock, Joanna Poczobutt, Mary Weiser-Evans, Raphael Nemenoff.

A90 Tumor associated PDL1 expression pattern in microscopically tumor positive sentinel lymph nodes (SLN) in patients with melanoma. *Ahmad A Tarhini*, Jennifer A Yearley, Christopher Gibson, Uma N. M. Rao, Cindy Sander, John M Kirkwood.

